Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project.


Journal

Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 15 10 2018
revised: 21 10 2018
accepted: 05 11 2018
pubmed: 15 11 2018
medline: 30 4 2019
entrez: 15 11 2018
Statut: ppublish

Résumé

The reliability of diagnostic criteria for invasive fungal diseases (IFD) developed for severely immunocompromised patients is questionable in critically ill adult patients in intensive care units (ICU). To develop a standard set of definitions for IFD in critically ill adult patients in ICU. Based on a systematic literature review, a list of potential definitions to be applied to ICU patients will be developed by the ESCMID Study Group for Infections in Critically Ill Patients (ESGCIP) and the ESCMID Fungal Infection Study Group (EFISG) chairpersons. The proposed definitions will be evaluated by a panel of 30 experts using the RAND/UCLA appropriateness methods. The panel will rank each of the proposed definitions on a 1-9 scale trough a dedicated questionnaire, in two rounds: one remote and one face-to-face. Based on their median rank and the level of agreement across panel members, selected definitions will be organised in a main consensus document and in an executive summary. The executive summary will be made available online for public comments. The present consensus project will seek to provide standard definitions for IFD in critically ill adult patients in ICU, with the ultimate aims of improving their clinical outcome and facilitating the comparison and generalizability of research findings.

Sections du résumé

BACKGROUND BACKGROUND
The reliability of diagnostic criteria for invasive fungal diseases (IFD) developed for severely immunocompromised patients is questionable in critically ill adult patients in intensive care units (ICU).
OBJECTIVES OBJECTIVE
To develop a standard set of definitions for IFD in critically ill adult patients in ICU.
METHODS METHODS
Based on a systematic literature review, a list of potential definitions to be applied to ICU patients will be developed by the ESCMID Study Group for Infections in Critically Ill Patients (ESGCIP) and the ESCMID Fungal Infection Study Group (EFISG) chairpersons. The proposed definitions will be evaluated by a panel of 30 experts using the RAND/UCLA appropriateness methods. The panel will rank each of the proposed definitions on a 1-9 scale trough a dedicated questionnaire, in two rounds: one remote and one face-to-face. Based on their median rank and the level of agreement across panel members, selected definitions will be organised in a main consensus document and in an executive summary. The executive summary will be made available online for public comments.
CONCLUSIONS CONCLUSIONS
The present consensus project will seek to provide standard definitions for IFD in critically ill adult patients in ICU, with the ultimate aims of improving their clinical outcome and facilitating the comparison and generalizability of research findings.

Identifiants

pubmed: 30426598
doi: 10.1111/myc.12869
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

310-319

Informations de copyright

© 2018 Blackwell Verlag GmbH.

Auteurs

Matteo Bassetti (M)

Infectious Diseases Clinic, Department of Medicine, University of Udine and Santa Maria Misericordia Hospital, Udine, Italy.

Luigia Scudeller (L)

Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Daniele R Giacobbe (DR)

Clinica Malattie Infettive, Ospedale Policlinico San Martino - IRCCS per l'Oncologia, Genoa, Italy.
Department of Health Sciences, University of Genoa, Genoa, Italy.

Frederic Lamoth (F)

Infectious Diseases Service, Department of Medicine, Lausanne University, Lausanne, Switzerland.
Institute of Microbiology, Lausanne University Hospital, Lausanne, Switzerland.

Elda Righi (E)

Infectious Diseases Clinic, Department of Medicine, University of Udine and Santa Maria Misericordia Hospital, Udine, Italy.

Valentina Zuccaro (V)

Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Cecilia Grecchi (C)

Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Chiara Rebuffi (C)

Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Murat Akova (M)

Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University Ankara, Ankara, Turkey.

Ana Alastruey-Izquierdo (A)

Spanish Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.

Sevtap Arikan-Akdagli (S)

Department of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Elie Azoulay (E)

AP-HP, Saint-Louis Hospital, Medical Intensive Care Unit, Paris (LZ, EA), ECSTRA Team, Biostatistics and Clinical Epidemiology, UMR 1153 INSERM, Paris Diderot, Sorbonne University, Paris, France.

Stijn I Blot (SI)

Department of Internal Medicine, Faculty of Medicine & Health Science, Ghent University, Ghent, Belgium.

Oliver A Cornely (OA)

Department I of Internal Medicine, University Hospital of Cologne and Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.

Cornelia Lass-Flörl (C)

Division of Hygiene and Medical Microbiology, Medical University Innsbruck, Innsbruck, Austria.

Philipp Koehler (P)

Department I of Internal Medicine, University Hospital of Cologne and Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.

Manuel Cuenca-Estrella (M)

Spanish Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.

Dylan W de Lange (DW)

Department of Intensive Care, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.

Francesco G De Rosa (FG)

Department of Medical Sciences, University of Turin, Turin, Italy.

Jan J De Waele (JJ)

Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium.

George Dimopoulos (G)

Department of Critical Care, University Hospital Attikon, Medical School, University of Athens, Athens, Greece.

José Garnacho-Montero (J)

Unidad Clínica de Cuidados Intensivos, Hospital Universitario Virgen Macarena and Institute of Biomedicine of Seville, IBiS/CSIC/University of Seville, Seville, Spain.

Martin Hoenigl (M)

Division of Infectious Diseases, Department of Medicine, University of California-San Diego, San Diego, California.
Section of Infectious Diseases and Tropical Medicine and Division of Pulmonology, Medical University of Graz, Graz, Austria.

Souha S Kanj (SS)

Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.

Johan Maertens (J)

Hematology, Department of Immunology and biology, KU Leuven, Leuven, Belgium.

Ignacio Martin-Loeches (I)

Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James's Hospital, Dublin, Ireland.

Patricia Muñoz (P)

Department of Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Instituto de Investigación Sanitaria Gregorio Marañón, CIBERES, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.

Bart J Kullberg (BJ)

Department of Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.

Christina Agvald-Ohman (C)

Department of Clinical Science, Intervention and Technology, Division of Anaesthesiology and Intensive Care, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden.

Garyphallia Poulakou (G)

3rd Department of Medicine, Medical School, Sotiria General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Jordi Rello (J)

CIBERES, Universitat Autonoma de Barcelona, Barcelona, Spain.

Maurizio Sanguinetti (M)

Institute of Microbiology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.

Fabio S Taccone (FS)

Department of Intensive Care, CUB - Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Jean-François Timsit (JF)

Université Paris Diderot/Hopital Bichat-Réanimation Medicale et Des Maladies Infectieuses, Paris, France.
UMR 1137-IAME Team 5-DeSCID: Decision Sciences in Infectious Diseases, Control and Care, Inserm/Univ Paris Diderot, Sorbonne Paris Cité, Paris, France.

Antoni Torres (A)

Department of Pulmonary Medicine, Hospital Clinic of Barcelona, University of Barcelona, CIBERES, IDIBAPS, Barcelona, Spain.

Jose A Vazquez (JA)

Department of Medicine, Division of Infectious Diseases, Medical College of Georgia/Georgia Regents University, Augusta, Georgia.

Thierry Calandra (T)

Infectious Diseases Service, Department of Medicine, Lausanne University, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH